Arpad Batai

Szekesfehervar, FE, Hungary

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

Second-line bosutinib for chronic phase chronic myeloid leukemia after imatinib: final, 10-year results of a phase I/II study.

Second-line bosutinib for chronic phase chronic myeloid leukemia after imatinib: final, 10-year results of a phase I/II study.

Journal: Haematologica

Published: November 13, 2025

The role of clonal hematopoiesis in the molecular diagnostics of solid tumors

The role of clonal hematopoiesis in the molecular diagnostics of solid tumors

Journal: Magyar onkologia

Published: September 25, 2024

Case Report: Effective management of adalimumab-induced acquired hemophilia A with the CyDRI protocol.

Case Report: Effective management of adalimumab-induced acquired hemophilia A with the CyDRI protocol.

Journal: Pathology oncology research : POR

Published: February 05, 2024

Low-burden TP53 mutations represent frequent genetic events in CLL with an increased risk for treatment initiation.

Low-burden TP53 mutations represent frequent genetic events in CLL with an increased risk for treatment initiation.

Journal: The journal of pathology. Clinical research

Published: July 26, 2023

Parallel testing of liquid biopsy (ctDNA) and tissue biopsy samples reveals a higher frequency of EZH2 mutations in follicular lymphoma.

Parallel testing of liquid biopsy (ctDNA) and tissue biopsy samples reveals a higher frequency of EZH2 mutations in follicular lymphoma.

Journal: Journal of internal medicine

Published: June 01, 2023

Randomized controlled study of ECP with methoxsalen as first-line treatment of patients with moderate to severe cGVHD.

Randomized controlled study of ECP with methoxsalen as first-line treatment of patients with moderate to severe cGVHD.

Journal: Blood advances

Published: March 12, 2019

Donor KIR2DS1 reduces the risk of transplant related mortality in HLA-C2 positive young recipients with hematological malignancies treated by myeloablative conditioning.

Donor KIR2DS1 reduces the risk of transplant related mortality in HLA-C2 positive young recipients with hematological malignancies treated by myeloablative conditioning.

Journal: PloS one

Published: January 02, 2019

Investigation of TGFB1 -1347C>T variant as a biomarker after allogeneic hematopoietic stem cell transplantation.

Investigation of TGFB1 -1347C>T variant as a biomarker after allogeneic hematopoietic stem cell transplantation.

Journal: Bone marrow transplantation

Published: December 20, 2018

Real World Efficacy and Safety Results of Ixazomib Lenalidomide and Dexamethasone Combination in Relapsed/Refractory Multiple Myeloma: Data Collected from the Hungarian Ixazomib Named Patient Program.

Real World Efficacy and Safety Results of Ixazomib Lenalidomide and Dexamethasone Combination in Relapsed/Refractory Multiple Myeloma: Data Collected from the Hungarian Ixazomib Named Patient Program.

Journal: Pathology oncology research : POR

Published: June 23, 2018

Sex-specific survival difference in association with HLA-DRB1∗04 following allogeneic haematopoietic stem cell transplantation for lymphoid malignancies.

Sex-specific survival difference in association with HLA-DRB1∗04 following allogeneic haematopoietic stem cell transplantation for lymphoid malignancies.

Journal: Human immunology

Published: June 19, 2017

Allogeneic hematopoietic stem cell transplantation in Hungary

Allogeneic hematopoietic stem cell transplantation in Hungary

Journal: Orvosi hetilap

Published: February 21, 2017

Recipient and donor JAK2 46/1 haplotypes are associated with acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.

Recipient and donor JAK2 46/1 haplotypes are associated with acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.

Journal: Leukemia & lymphoma

Published: July 09, 2016

Showing 1-12 of 20

Last Updated: 09/26/2026